Overview

[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours

Status:
Terminated

Trial end date:
2019-02-04

Target enrollment:

Participant gender:

Summary

Positron Emission Tomography (PET) is a Nuclear Medicine procedure that uses positron emitting radiolabeled tracer molecules to visualize biological activity. The presence of hypoxia (low oxygen) is associated with poor prognosis in a variety of tumour types and treatment strategies targeting hypoxic cells have been developed. The PET tracer [18]F-FAZA can identify hypoxic areas, and changes in uptake during treatment may predict tumour response.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

AHS Cancer Control Alberta

Treatments:

Fluoroazomycin arabinoside